Apollo Consulting & Trading AG advised Swiss-based biotechnology company
Biotensidon International AG in all legal matters concerning the build-up of
international production capacity for rhamnolipids (natural surfactants).
These activities include drafting the company’s IPO strategy and acting as
lead consultancy for setting up strategic joint ventures of a German
Biotensidon subsidiary with leading key players in their respective
industries, among others with global and European market leaders in animal
feed production, in the fertilizer industry and the detergents sector.
Biotensidon has recently achieved a biotechnological breakthrough and is now
the first company in the world to be able to mass-produce
microorganism-based rhamonlipid bio-surfactants on an industrial scale.
Until recently, the global rhamnolipds market was characterized by extremely
high prices and too-low-to-matter quantities of rhamnolipids, due to limited
Biotensidon’s breakthrough and its current
investments in production capacity for 2.000 tons by 2018 will change this
situation. As demand for bio-surfactants will soar in the upcoming years,
Biotensidon is likely to be instrumental in building the global commercial
market for rhamnolipids.
From the beginning of the project, Apollo’s partner Mr. Mark Gössel was part
of Biotensidon’s integrated JV team and was involved in drafting appropriate
strategies for the multi-million Euro deals and the initial public offering
(IPO), which is set to take place at Zurich Stock Exchange in 2017.
Providing insight in relevant aspects of corporate and tax law, Mr. Gössel
was influential in planning the JVs’ structure. He also led negotiations
with Biotensidon’s JV partners and served on the due diligence task force.